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9 Appendix D: further references
The references which are reported here have been divided in different subsec-
tions. The first subsection refers to the courses attended during this vising period; the
second subsection refers to a selection of WWW sites which have been frequently
accessed during this work. Finally, the other two subsections refers to a greater list
of references on CommonKADS and on breast cancer prognosis and treatment which
might be useful for readers interested in this field.
9.1 Attended courses and publication produced in relation to this
work
European School of Oncology - Advanced Course: Breast Cancer, 2nd-4th
October, 1995, Milan, Italy. Chairman of the Scientific Committee Prof. U.Veronesi.
Chairman of the Course/Seminar Prof. J-Y. Petit, Dr. D.W.Kinne.
Sacile, R., Ruggiero, C., Dieng, R., Applicazione ed uso di CommonKADS
per creare un modello concettuale per la prognosi del tumore della mammella. Con-
gresso Annuale Aica (Associazione Italiana per l’Informatica ed il Calcolo Automa-
tico), vol.2, pp. 691-696.
9.2 List of WWW server
9.2.1. On Cancer Information
• http://golgi.harvard.edu/biopages/medicine.html












    type : primitive ;
    sub-tasks : cover ;
    control-structure :
    generate(c:initial_complaint -> h:hypothesis) =
        cover(c:initial_complaint -> h:hypothesis) ;
task test ;
task-definition
    goal : «test the risk» ;
    input : initial_complaint : «risk value» ;
    output : hypothesis : «risk value» ;
task-body
    type : primitive ;
    sub-tasks : match ;
    control-structure :
    test(c:risk1 -> h:risk2) =
     match(c:risk1 -> h:risk2);
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--inference establish
    --operation-type : backwardall ;
    --input-roles : initial_complaint -> state ;
    --output-roles : hypothesis -> state ;
    --static-roles : necessary_condition -> cause in
causal_model ;




    goal : «define the bc risk» ;
    input : initial_complaint : «a» ; biol_manifestation :
«b» ;
    output : prognosis : «c» ;
    specification : «assess the bc risk, confirm by addi-
tional biol_manifestation» ;
task-body
    type : primitive ;
    sub-tasks : generate_biol , generate ;
    additional-roles : hypothesis : «» ;
    control-structure :
    bc_prognosis(c:initial_complaint, m:biol_manifestation
-> h:prognosis) =
        generate_biol(m:biol_manifestation -> d:complaint) ;
        generate(d:complaint -> h1:hypothesis) ;
        generate(c:initial_complaint -> h2:hypothesis) ;
        test(h1:hypothesis -> h: prognosis);
        test(h2:hypothesis -> h: prognosis);
task generate_biol ;
task-definition
    goal : «generate a biol risk fact» ;
    input : initial_complaint : «» ;
    output : hypothesis : «» ;
task-body
    type : primitive ;
    sub-tasks : cover ;
    control-structure :
    generate(c:initial_complaint -> h:hypothesis) =
        cover_biol(c:initial_complaint -> h:hypothesis) ;
task generate ;
task-definition
    goal : «generate a possible risk» ;
    input : initial_complaint : «» ;
    output : hypothesis : «» ;
task-body
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status of Thymidine_labeling_index = high
status of Proliferative_capacity = low
has_biol_manifestation
status of S_phase_fraction = low
status of Proliferative_capacity = high
has_biol_manifestation
status of S_phase_fraction = high
status of Proliferative_capacity = high
has_biol_manifestation
status of S_phase_fraction = medium
;
domain-model : risk_model ; uses : breast_cancer ;
rules :
status of final_risk = high
caused_by_risk
status of risk = high
status of final_risk = low
caused_by_risk




    operation-type : backward ;
    input-roles : initial_complaint -> state ;
    output-roles : hypothesis -> state ;
    static-roles : potential_cause -> caused_by in
causal_model;
    specification : «any» ;
inference cover_biol
    operation-type : backward ;
    input-roles : initial_complaint -> state ;
    output-roles : hypothesis -> state ;
    static-roles : biol_cause ->  has_biol_manifestation in
behavioral_model;
    specification : «any» ;
inference match
    operation-type : backward;
    input-roles : risk1 -> state ;
    output-roles : risk2 -> state ;
    static-roles : produce ->  caused_by_risk in risk_model;
    specification : «any» ;
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relation has_biol_manifestation ;
    argument-1 : state ;
                 argument-role : cause ;
    argument-2 : biol_manifestation ;
                 argument-role : effect ;
relation caused_by_risk;
    argument-1 : state ;
                 argument-role : cause ;
    argument-2 : state ;
                 argument-role : effect ;
domain-model : causal_model ; uses : breast_cancer ;
--status of Size = little and--status of axillary_nodes =
negative and--status of ER = positive and--status of
Proliferative_capacity = low--cause--status of risk = low
rules :
status of risk = high
caused_by
status of Size = big
status of risk = high
caused_by
status of axillary_nodes = positive
status of risk = high
caused_by
status of ER = negative
status of risk = high
caused_by
status of Proliferative_capacity = high
;
domain-model : behavioral_model ; uses : breast_cancer ;
rules :
status of Proliferative_capacity = low
has_biol_manifestation
status of Ploidy = aneuploid
status of Proliferative_capacity = high
has_biol_manifestation
status of Ploidy = diploid
status of Proliferative_capacity = low
has_biol_manifestation
status of Thymidine_labeling_index = low
status of Proliferative_capacity = high
has_biol_manifestation
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        status : {low, high} ;
            differentiation-of
state_variable(Primary_tumor_prognostic_factor) ;
concept Thymidine_labeling_index ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {low, high} ;
            differentiation-of
observable_variable(Primary_tumor_prognostic_factor) ;
concept S_phase_fraction ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {low, medium, high} ;
            differentiation-of
observable_variable(Primary_tumor_prognostic_factor) ;
concept Ploidy ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {diploid, aneuploid} ;
            differentiation-of
observable_variable(Primary_tumor_prognostic_factor) ;
expression state ;
    description : «status of Size = big» ;
    operand : state_variable of
Primary_tumor_prognostic_factor ;
expression biol_manifestation ;
    operand : observable_variable of
Primary_tumor_prognostic_factor ;
expression risk_factor ;
description : «status of risk = high» ;
operand : status of risk;
relation cause ;
    inverse : caused_by ;
    argument-1 : state ;
                 argument-role : cause ;
    argument-2 : state ;
                 argument-role : effect ;
relation caused_by ;
    inverse : cause ;
    argument-1 : state ;
                 argument-role : cause ;
    argument-2 : state ;
                 argument-role : effect ;
Using CommonKADS to build an expertise model for breast cancer prognosis and therapy
71







    properties :
        observable_variable : universal ;
        state_variable : universal ;
concept risk ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {high, low} ;
            differentiation-of
state_variable(Primary_tumor_prognostic_factor) ;
concept final_risk ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {high, low} ;
            differentiation-of
state_variable(Primary_tumor_prognostic_factor) ;
concept Size ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {big, little} ;
            differentiation-of
state_variable(Primary_tumor_prognostic_factor) ;
concept axillary_nodes ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {positive, negative} ;
            differentiation-of
state_variable(Primary_tumor_prognostic_factor) ;
concept ER ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
        status : {positive, negative} ;
            differentiation-of
state_variable(Primary_tumor_prognostic_factor) ;
concept Proliferative_capacity ;
    sub-type-of : Primary_tumor_prognostic_factor ;
    properties :
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      ARGUMENT2  :CONCEPT Size
      AXIOMS     :
      axiom 1    :IF Size(level) = [0-1]
                  THEN Positive axillary nodes(level) = 20
      axiom 2    :IF Size(level) = [1-2.9]
                  THEN Positive axillary nodes(level) = 39
      axiom 3    :IF Size(level) = [2.9-infinite]
                  THEN Positive axillary nodes(level) = 69
   END RELATION (Positive axillary nodes) depend from (Size)
   Relation
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                  [Size(level) = unknown]
   ND RELATION (Size) depend from (S-phase fraction)
   Relation
   *
   RELATION (Positive axillary nodes) depend from (Ploidy)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Positive axillary nodes
      ARGUMENT2  :CONCEPT Ploidy
      AXIOMS     :
      axiom 1    :IF Ploidy(status)=diploid
                  THEN {with probability=0.64}
                  [Positive axillary nodes(status) = null]
                  OR {with probability=0.36}
                  [Positive axillary nodes(status) = low/high]
      axiom 2    :IF Ploidy(status)=aneuploid
                  THEN {with probability=0.59}
                  [Positive axillary nodes(status) = null]
                  OR {with probability=0.41}
                  [Positive axillary nodes(status) = low/high]
   END RELATION (Positive axillary nodes) depend from (Ploi-
dy)
   Relation
   *
   RELATION (Positive axillary nodes) depend from (S-phase
fraction)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Positive axillary nodes
      ARGUMENT2  :CONCEPT S-phase fraction
      AXIOMS     :
      axiom 1    :IF S-phase fraction(status)=low
                  THEN {with probability=0.65}
                  [Positive axillary nodes(status) = null]
                  OR {with probability=0.35}
                  [Positive axillary nodes(status) = low/high]
      axiom 2    :IF S-phase fraction(status)=high
                  THEN {with probability=0.58}
                  [Positive axillary nodes(status) = null]
                  OR {with probability=0.42}
                  [Positive axillary nodes(status) = low/high]
   END RELATION (Positive axillary nodes) depend from (S-
phase fraction)
   *
   RELATION (Positive axillary nodes) depend from (Size)
      SOURCES    :Neoplasie della mammella(622)
      ARGUMENT1  :CONCEPT Positive axillary nodes
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   RELATION (Size) depend from (Ploidy)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Size
      ARGUMENT2  :CONCEPT Ploidy
      AXIOMS     :
      axiom 1    :IF Ploidy(status)=diploid
                  THEN {with probability=0.34}
                  [Size(level) = [0-2]
                  OR {with probability=0.41}
                  [Size(level) = [2-4]
                  OR {with probability=0.24}
                  [Size(level) = [4-infinite]
                  OR {with probability=0.1}
                  [Size(level) = unknown]
      axiom 2    :IF Ploidy(status)=aneuploid
                  THEN {with probability=0.23}
                  [Size(level) = [0-2]]
                  OR {with probability=0.44}
                  [Size(level) = [2-4]]
                  OR {with probability=0.32}
                  [Size(level) = [4-infinite]]
                  OR {with probability=0.1}
                  [Size(level) = unknown]
   END RELATION (Size) depend from (Ploidy)
   Relation
   *
   RELATION (Size) depend from (S-phase fraction)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Size
      ARGUMENT2  :CONCEPT S-phase fraction
      AXIOMS     :
      axiom 1    :IF S-phase fraction(status)=low
                  THEN {with probability=0.32}
                  [Size(level) = [0-2]
                  OR {with probability=0.44}
                  [Size(level) = [2-4]
                  OR {with probability=0.23}
                  [Size(level) = [4-infinite]
                  OR {with probability=0.1}
                  [Size(level) = unknown]
      axiom 2    :IF S-phase fraction(status)=high
                  THEN {with probability=0.25}
                  [Size(level) = [0-2]
                  OR {with probability=0.43}
                  [Size(level) = [2-4]
                  OR {with probability=0.32}
                  [Size(level) = [4-infinite]
                  OR {with probability=0}
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   RELATION (Nuclear grade) depend from (Ploidy)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Nuclear grade
      ARGUMENT2  :CONCEPT Ploidy
      AXIOMS     :
      axiom 1    :IF Ploidy(status)=diploid
                  THEN {with probability=0.27}
                  [Nuclear grade(status) = poor]
                  OR {with probability=0.72}
                  [Nuclear grade(status) = good]
                  OR {with probability=0.1}
                  [Nuclear grade(status) = unknown]
      axiom 2    :IF Ploidy(status)=aneuploid
                  THEN {with probability=0.44}
                  [Nuclear grade(status) = poor]
                  OR {with probability=0.55}
                  [Nuclear grade(status) = good]
                  OR {with probability=0.1}
                  [Nuclear grade(status) = unknown]
   END RELATION (Nuclear grade) depend from (Ploidy)
   Relation
   *
   RELATION (Nuclear grade) depend from (S-phase fraction)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Nuclear grade
      ARGUMENT2  :CONCEPT S-phase fraction
      AXIOMS     :
      axiom 1    :IF S-phase fraction(status)=low
                  THEN {with probability=0.28}
                  [Nuclear grade(status) = poor]
                  OR {with probability=0.71}
                  [Nuclear grade(status) = good]
                  OR {with probability=0.1}
                  [Nuclear grade(status) = unknown]
      axiom 2    :IF S-phase fraction(status)=high
                  THEN {with probability=0.45}
                  [Nuclear grade(status) = poor]
                  OR {with probability=0.54}
                  [Nuclear grade(status) = good]
                  OR {with probability=0.1}
                  [Nuclear grade(status) = unknown]
   END RELATION  (Nuclear grade) depend from (S-phase frac-
tion)
   Relation
   *
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                  OR {with probability=0.44}
                  [Grading(status) = 3]
   END RELATION (Grading) depend from(ER)
   Relation
   *
   RELATION (Age) depend from (Ploidy)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Age
      ARGUMENT2  :CONCEPT Ploidy
      AXIOMS     :
      axiom 1    :IF Ploidy(status)=diploid
                  THEN {with probability=0.3}
                  [Age(level) = [0-49]]
                  OR {with probability=0.7}
                  [Age(level) = [50-150]]
      axiom 2    :IF Ploidy(status)=aneuploid
                  THEN {with probability=0.33}
                  [Age(level) = [0-49]]
                  OR {with probability=0.67}
                  [Age(level) = [50-150]]
   END RELATION (Age) depend from (Ploidy)
   Relation
   *
   RELATION (Age) depend from (S-phase fraction)
      SOURCES    :Cancer 68:(1469)
      ARGUMENT1  :CONCEPT Age
      ARGUMENT2  :CONCEPT S-phase fraction
      AXIOMS     :
      axiom 1    :IF S-phase fraction(status)=low
                  THEN {with probability=0.31}
                  [Age(level) = [0-49]]
                  OR {with probability=0.69}
                  [Age(level) = [50-150]]
      axiom 2    :IF S-phase fraction(status)=high
                  THEN {with probability=0.33}
                  [Age(level) = [0-49]]
                  OR {with probability=0.67}
                  [Age(level) = [50-150]]
   END RELATION (Age) depend from (S-phase fraction)
   Relation
   *
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   Relation
   *
   RELATION (Grading) depend from (Peritumoral lymphatic
vessel invasion)
      SOURCES    :Cancer 58:(2665)
      ARGUMENT1  :CONCEPT Grading
      ARGUMENT2  :CONCEPT Peritumoral lymphatic vessel in-
vasion
      AXIOMS     :
      axiom 1    :IF Peritumoral lymphatic vessel inva-
sion(status)=Positive
                  THEN {with probability=0.28}
                  [Grading(status) = 1]
                  OR {with probability=0.48}
                  [Grading(status) = 2]
                  OR {with probability=0.24}
                  [Grading(status) = 3]
      axiom 2    :IF Peritumoral lymphatic vessel inva-
sion(status)=negative
                  THEN {with probability=0.18}
                  [Grading(status) = 1]
                  OR {with probability=0.49}
                  [Grading(status) = 2]
                  OR {with probability=0.33}
                  [Grading(status) = 3]
   END RELATION (Grading) depend from (Peritumoral lymphat-
ic vessel invasion)
   Relation
   *
   RELATION (Grading) depend from(ER)
      SOURCES    :Cancer 58:(2665)
      ARGUMENT1  :CONCEPT Grading
      ARGUMENT2  :CONCEPT ER
      AXIOMS     :
      axiom 1    :IF ER(status)=Positive
                  THEN {with probability=0.29}
                  [Grading(status) = 1]
                  OR {with probability=0.52}
                  [Grading(status) = 2]
                  OR {with probability=0.19}
                  [Grading(status) = 3]
      axiom 2    :IF ER(status)=negative
                  THEN {with probability=0.12}
                  [Grading(status) = 1]
                  OR {with probability=0.44}
                  [Grading(status) = 2]
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node)
   Relation
   *
   RELATION (Grading) depend from (Menopause)
      SOURCES    :Cancer 58:(2665)
      ARGUMENT1  :CONCEPT Grading
      ARGUMENT2  :CONCEPT Menopause
      AXIOMS     :
      axiom 1    :IF Menopause(status)=pre
                  THEN {with probability=0.21}
                  [Grading(status) = 1]
                  OR {with probability=0.48}
                  [Grading(status) = 2]
                  OR {with probability=0.31}
                  [Grading(status) = 3]
      axiom 2    :IF Menopause(status)=post
                  THEN {with probability=0.24}
                  [Grading(status) = 1]
                  OR {with probability=0.50}
                  [Grading(status) = 2]
                  OR {with probability=0.26}
                  [Grading(status) = 3]
   END RELATION (Grading) depend from (Menopause)
   Relation
   *
   RELATION (Grading) depend from (Size)
      SOURCES    :Cancer 58:(2665)
      ARGUMENT1  :CONCEPT Grading
      ARGUMENT2  :CONCEPT Size
      AXIOMS     :
      axiom 1    :IF Size(status)=T1
                  THEN {with probability=0.28}
                  [Grading(status) = 1]
                  OR {with probability=0.47}
                  [Grading(status) = 2]
                  OR {with probability=0.25}
                  [Grading(status) = 3]
      axiom 2    :IF Size(status)=T2-3
                  THEN {with probability=0.18}
                  [Grading(status) = 1]
                  OR {with probability=0.50}
                  [Grading(status) = 2]
                  OR {with probability=0.32}
                  [Grading(status) = 3]
   END RELATION (Grading) depend from (Size)
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                  [Size(status) = T0-1]
                  OR {with probability=0.46}
                  [Size(status) = T2]
                  OR {with probability=0.22}
                  [Size(status) = T3]
                  OR {with probability=0.6}
                  [Size(status) = T4]
      axiom 2    :IF Age(level)=[34-40]
                  THEN {with probability=0.34}
                  [Size(status) = T0-1]
                  OR {with probability=0.44}
                  [Size(status) = T2]
                  OR {with probability=0.18}
                  [Size(status) = T3]
                  OR {with probability=0.4}
                  [Size(status) = T4]
       axiom 3   :IF Age(level)=[40-150]
                  THEN {with probability=0.31}
                  [Size(status) = T0-1]
                  OR {with probability=0.46}
                  [Size(status) = T2]
                  OR {with probability=0.17}
                  [Size(status) = T3]
                  OR {with probability=0.6}
                  [Size(status) = T4]
   END RELATION (Size) depend from (Age)
   Relation
   *
   RELATION (Grading) depend from (Positive axillary node)
      SOURCES    :Cancer 58:(2665)
      ARGUMENT1  :CONCEPT Grading
      ARGUMENT2  :CONCEPT Positive axillary node
      AXIOMS     :
      axiom 1    :IF Positive axillary node(status)=low
                  THEN {with probability=0.26}
                  [Grading(status) = 1]
                  OR {with probability=0.46}
                  [Grading(status) = 2]
                  OR {with probability=0.28}
                  [Grading(status) = 3]
      axiom 2    :IF Positive axillary node(status)=high
                  THEN {with probability=0.18}
                  [Grading(status) = 1]
                  OR {with probability=0.52}
                  [Grading(status) = 2]
                  OR {with probability=0.30}
                  [Grading(status) = 3]
   END RELATION (Grading) depend from (Positive axillary
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   *
   RELATION (Positive axillary node) depend from (Age)
      SOURCES    :The Lancet 1990:335:(1566)
      ARGUMENT1  :CONCEPT Positive axillary node
      ARGUMENT2  :CONCEPT Age
         AXIOMS  :
         axiom 1 :IF Age(level)=[0-29]
                  THEN {with probability=0}
                  Positive axillary node(level) > 0
                  OR {with probability=1}
                  Positive axillary node(level) = 0
         axiom 2 :IF Age(level)=[30-39]
                  THEN {with probability=0.12}
                  Positive axillary node(level) > 0
                  OR {with probability=0.87}
                  Positive axillary node(level) = 0
         axiom 3 :IF Age(level)=[40-49]
                  THEN {with probability=0.12}
                  Positive axillary node(level) > 0
                  OR {with probability=0.88}
                  Positive axillary node(level) = 0
         axiom 4 :IF Age(level)=[50-59]
                  THEN {with probability=0.7}
                  Positive axillary node(level) > 0
                  OR {with probability=0.93}
                  Positive axillary node(level) = 0
         axiom 5 :IF Age(level)=[60-69]
                  THEN {with probability=0.8}
                  Positive axillary node(level) > 0
                  OR {with probability=0.92}
                  Positive axillary node(level) = 0
         axiom 6 :IF Age(level)=[70-150]
                  THEN {with probability=0}
                  Positive axillary node(level) > 0
                  OR {with probability=1}
                  Positive axillary node(level) = 0
   END RELATION (Positive axillary node) depend from (Age)
   Relation
   *
   RELATION (Size) depend from (Age)
      SOURCES    :The Lancet(1040)
      ARGUMENT1  :CONCEPT Size
      ARGUMENT2  :CONCEPT Age
      AXIOMS     :
      axiom 1    :IF Age(level)=[0-33]
                  THEN {with probability=0.26}
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                  OR {with probability=0.56}
                  [ER(level) not determined
         axiom 2 :IF  Age(level)=[34-40]
                  THEN {with probability=0.30}
                  [ER(level) > 250 fmol/mg
                  OR {with probability=0.13}
                  [ER(level) < 250 fmol/mg
                  OR {with probability=0.57}
                  [ER(level) not determined
         axiom 3 :IF  Age(level)=[40-150]
                  THEN {with probability=0.31}
                  [ER(level) > 250 fmol/mg
                  OR {with probability=0.11}
                  [ER(level) < 250 fmol/mg
                  OR {with probability=0.58}
                  [ER(level) not determined
   END RELATION (ER) depend from (Age)
   Relation
   *
   RELATION (PR) depend from (Age)
      SOURCES    :The Lancet 1993:341:1040
      ARGUMENT1  :CONCEPT PR
      ARGUMENT2  :CONCEPT Age
      AXIOMS     :
         axiom 1 :IF Age(level)=[0-33]
                  THEN {with probability=0.41}
                  [PR(level) > 250 fmol/mg
                  OR {with probability=0.26}
                  [PR(level) < 250 fmol/mg
                  OR {with probability=0.33}
                  [PR(level) not determined
         axiom 4 :IF Age(level)=[34-40]
                  THEN {with probability=0.52}
                  [PR(level) > 250 fmol/mg
                  OR {with probability=0.20}
                  [PR(level) < 250 fmol/mg
                  OR {with probability=0.28}
                  [PR(level) not determined
         axiom 7 :IF Age(level)=[40-150]
                  THEN {with probability=0.51}
                  [PR(level) > 250 fmol/mg
                  OR {with probability=0.20}
                  [PR(level) < 250 fmol/mg
                  OR {with probability=0.29}
                  [PR(level) not determined
   END RELATION (PR) depend from (Age)
   Relation
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Some relations in the domain model
Relation
go to prognostic factor
   (Menopause) depend from (Age)
   (ER) depend from (Age)
   (PR) depend from (Age)
   (Positive axillary node) depend from (Age)
   (Size) depend from (Age)
   (Grading) depend from (Positive axillary node)
   (Grading) depend from (Menopause)
   (Grading) depend from (Size)
   (Grading) depend from (Peritumoral lymphatic vessel in-
vasion)
   (Grading) depend from(ER)
   (Age) depend from (Ploidy)
   (Age) depend from (S-phase fraction)
   (Nuclear grade) depend from (Ploidy)
   (Nuclear grade) depend from (S-phase fraction)
   (Size) depend from (Ploidy)
   (Size) depend from (S-phase fraction)
   (Positive axillary nodes) depend from (Ploidy)
   (Positive axillary nodes) depend from (S-phase fraction)
   (Positive axillary nodes) depend from (Size)
   *
   RELATION (Menopause) depend from (Age)
      ARGUMENT1  :CONCEPT Menopause
      ARGUMENT2  :CONCEPT Age
      AXIOMS     :IF Age(level)=[0-50]
                  THEN [menopause(status) = pre]
                  IF Age(level)=[50-150]
                  THEN [menopause(status) = post]
   END RELATION (Menopause) depend from (Age)
   Relation
   *
   RELATION (ER) depend from (Age)
      SOURCES    :(The Lancet 1993:341:1040)
      ARGUMENT1  :CONCEPT ER
      ARGUMENT2  :CONCEPT Age
      AXIOMS     :
         axiom 1 :IF Age(level)=[0-33]
                  THEN {with probability=0.28}
                  [ER(level) > 250 fmol/mg
                  OR {with probability=0.16}
                  [ER(level) < 250 fmol/mg
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        (T*  and  N3  and  M0)









   DESCRIPTION: oncogene whose level is measured by
                immunoperoxidase procedure
   SYNONYMS: erbB-2; HER2/neu;
   SOURCES    :Cancer Research 52,1107-1113,1992
               Journal of Clinical Oncology 10(7):1044-
1048,1992
               Journal of Clinical Oncology 8(1):103-112,1990
   SUB TYPE OF:Oncogene expression
   PROPERTIES:
      status    :{positive ,negative}
      level     :{-,+,++}
   AXIOMS:
      positive:level = {++}





   DESCRIPTION:clinical classification of brast cancer
(1992)
                -T:primary Tumor size
                -N:lymph Node status
                -M:distant metastasis
   SOURCES    :G.Bonadonna, Breast neoplasia(622)
   SUB TYPE OF:Size AND Axillary nodes AND metastasis
   PROPERTIES:
      stages    :{0,I,IIA;IIB,IIIA,IIIB,IV}
   AXIOMS:
      0:(Tis and  N0  and  M0)
      I:(T1  and  NO  and  M0)
    IIA:(T0  and  N1  and  M0) or
        (T1  and  N1  and  M0) or
        (T2  and  N0  and  M0)
    IIB:(T2  and  N1  and  M0) or
        (T3  and  N0  and  M0)
   IIIA:(T0  and  N2  and  M0) or
        (T1  and  N2  and  M0) or
        (T2  and  N2  and  M0) or
        (T3  and  N1  and  M0) or
        (T3  and  N2  and  M0)
   IIIB:(T4  and  N*  and  M0) or
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      status:{low,middle,high}
   AXIOMS:
      low   :(0-7)
      middle:(7-11.9)
      high  :(12-100)




   DESCRIPTION:prolification indicator
   SOURCES    :Cancer 68:1465-1475,1991
   SUB TYPE OF:proliferative capacity
   PROPERTIES:





   DESCRIPTION:whatever agent which is able to cause cancer;
it is generally used for proteins whose presence is related
to cancer.
   SUB TYPE OF:biologic




   DESCRIPTION:oncogene
   SOURCES    :Cancer Research 52,1107-1113,1992
   SUB TYPE OF:oncogene expression
   PROPERTIES:





   DESCRIPTION:protein oncogene
   SOURCES    :Journal of Clinical Oncology 12(3):454-
466,1994
   SUB TYPE OF:Oncogene expression
   PROPERTIES:
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               8(6):1025-1035,1990
   SUB TYPE OF:Hormonal receptor
   PROPERTIES:
      unit       :{fmol/mg}
      level      :NUMBER-RANGE(0-infinite)
      status      :{positive,negative}
   AXIOMS:
      positive:INTEGER-RANGE(0-9)





   DESCRIPTION:proliferative activity gives information on
the reproduction speed of the tumoral cells.
   SOURCES    :The New England Journal of Medi-
cine(322):1045-1053
   SUB TYPE OF:Biologic
   PROPERTIES:
      status    :{low,high}
END CONCEPT Proliferative capacity
Concept
*
CONCEPT Thymidine labeling index
   DESCRIPTION: proliferative index given by the thymidine
index
   SUB TYPE OF:Proliferative capacity
   PROPERTIES:
      status    :{low,high}
END CONCEPT Thymidine labeling index
Concept
*
CONCEPT  S-phase fraction
   DESCRIPTION: proliferative index given by
                the fraction of cells in phase S.
               (Flow cytometric measurements)
   SOURCES    :Cancer 68:1465-1475,1991
               The New England Journal of Medicine(322)
               :1045-1053
   SUB TYPE OF:Proliferative capacity
   PROPERTIES:
      unit:{%}




   DESCRIPTION: biologic prognostic factors





   DESCRIPTION:descriptors of hormonal substances
   TYPE OF:Biologic




   DESCRIPTION:estrogen are hormonal substances which fa-
vour the female growth, whose level is related to the mor-
tality of breast cancer. A risk level (10 fmol/mg) has been
so defined.
   SOURCES    :Breast Cancer Research and Treatment
               7(3):147-160,1986
               Journal of Clinical Oncology
               8(6):1025-1035,1990
   SUB TYPE OF:Hormonal receptor
   PROPERTIES:
      unit       :{fmol/mg}
      level      :NUMBER-RANGE(0-infinite)
      status      :{positive,negative}
   AXIOMS:
      positive:INTEGER-RANGE(0-9)





   DESCRIPTION:progesteron is an hormonal substance, whose
                level is related to the mortality of breast
                cancer. A risk level (10 fmol/mg) has been so
                defined.
   SOURCES    :Breast Cancer Research and Treatment
               7(3):147-160,1986
               journal of clinical oncology
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   DESCRIPTION:
        Nearly quantitative evaluation of the grade of ma-
lignant of the tumor based in terms of histologic parame-
ters on a microscopic point of view. The following parame-
ters are evalueted:tubular formation, nuclear polymorphism
(irregularity in the dimension) and mitosi
      Specifically:
      Tubular formation:T
      1 score:well-defined
      2 score:medium
      3 score:low
      Polymorphism:P
      1 scorepunto:isomorph
      2 score:low in dimension, form and structure
      3 score:high
      Mitosi:M
      (peripheric exam in the sites of the tumor in which
       neoplastic tissue is present)
      1 score:occasional mitotic patterns
      2 score:two or three mitotic pattern observed
      3 score:high number of mitotic patterns
   SOURCES    :Cancer 65:2121-2128,1990;Cancer 58:2662-
2670,1986
   SUB TYPE OF:Morphologic
   PROPERTIES:
      T level:INTEGER RANGE(1-3)
      P level:INTEGER RANGE(1-3)
      M level:INTEGER RANGE(1-3)
      level  :INTEGER RANGE(3-9)
      status :{I,II,III}
   AXIOMS:
      level = T level+P level+M level
      I  :level=[3-5]
      II :level=[6-7]





   DESCRIPTION:Semiquantitative evaluation of cytologic pa-
rameters
   SOURCES    :Cancer 65:2121-2128,1990;Cancer 58:2662-
2670,1986
   SUB TYPE OF:Primary tumor prognostic factor
   PROPERTIES:
      status:{poor,good,unknown}
END CONCEPT Cellular
Concept
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   SUB TYPE OF:Morphologic
   PROPERTIES:
      status:{positive,negative};




CONCEPT Serial sectioning of ipsilateral axillary lymphn-
odes
   SOURCES    :Lancet(335);1565-1568,1990
   SUB TYPE OF:morphologic
   PROPERTIES:
      status:{positive,negative};
      lynph node: NOMINAL;




CONCEPT Tumor microvessels density
   SOURCES    :Journal of Clinical Oncology 12(3):454-
466,1994
   SUB TYPE OF:morphologic
   PROPERTIES:
      status:{positive,negative};
END CONCEPT Tumor microvessels density
Concept
*
CONCEPT Peritumoral lymphatic vessel invasion
   DESCRIPTION:nearly the 30% of breast cancers have an in-
vasion of the peritumoral lymphatic vessels (external to
the tumor) in the form of tumor embol. The tumor embol are
groups of neoplastic cells come off from tumor mass.
   SOURCES    :G.Bonadonna, Breast neoplasia(622)
   SUB TYPE OF:morphologic
   PROPERTIES:
      status:{positive,negative}








   DESCRIPTION: reproduction of the tumor at distance, due
to the infiltration of cancer cells in the lymphantic or
circuation system.
   SOURCES    :Lancet(335);1565-1568,1990
   SUB TYPE OF:Anatomic stage
   PROPERTIES:
      status :{N0,N1,N2,N3,MX,M0,M1 }
   AXIOMS :
      N0  :no metastasis in regional lymph nodes
      N1  :metastasis in mobile homolateral axillary lymph
nodes
      N2  :metastasis in fix homolateral axillary lymph nodes
      N3  :metastasis in omolateral internal mammary lymph
nodes
      Mx  :distant metastasis not checked
      M0  :no distant metastasis





   DESCRIPTION: histologic (that is regarding the tissue)
prognostic factors




   DESCRIPTION: morphologic (that is regarding the forme
and the structure) prognostic factors





   DESCRIPTION:necrosis is a complex of irreversible alter-
ations of cellular, tissue, organ structure which implies
their loss of living activity
   SOURCES    :journal of clinical oncology 11(10):1929-
1935, 1993
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CONCEPT Anatomic stage
   DESCRIPTION:Prognostic factors from an anatomic point of
view. Anatomy studies the form and the structure of living
being both from a microscopic and from a macroscopic point
of view.
   SUB TYPE OF:Primary tumor prognostic factor
END CONCEPT Anatomic stage
Concept
*
CONCEPT Positive axillary nodes
   DESCRIPTION:it is the most powerful prognostic factor;
               it describes the presence of lymphnodes in
the axillary areas, which have been affected by the tumor,
and as a consequence, in the dimension. In the case a lymph
node is not affected, is classified as negative.
   SOURCES    :Lancet 335(8705):1565-1568,1990
   SUB TYPE OF:Anatomic stage
   PROPERTIES:
      level         :INTEGER-RANGE(0-infinite);
      status        :{null,low,high}
   AXIOMS:
      null  :NULL
      low   :INTEGER-RANGE(1-3)
      high  :INTEGER-RANGE(4-INFINITE)




   DESCRIPTION:dimension of the primary tumor, expressed in
cm.
   SUB TYPE OF:Anatomic stage
   PROPERTIES:
      unit          :{cm}
      level         :NUMBER-RANGE(0,infinite);
      status        :{T0,T1,T1a,T1b,T1c,T2,T3,unknown}
   AXIOMS:
         T0 :NULL
         T1 :INTEGER-RANGE(0-2)
         T1a:INTEGER-RANGE(0-0.5)
         T1b:INTEGER-RANGE(0.5-1)
         T1c:INTEGER-RANGE(1-2)
         T2:INTEGER-RANGE(2-5)
         T3:INTEGER-RANGE(5-infinite)
         T4:whatever dimension, but with direct extension
to the
            chest wall or to the skin.
END CONCEPT Size
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The primary tumor prognostic factor domain
Concept
go to Prognostic factor
go to relation
   Primary tumor prognostic factor
      Anatomic stage
         Size
            TNMstage
         Positive axillary nodes
            TNMstage
         metastasis
            TNMstage
      Histologic
         Morphologic
            Grading
            Cellular
            Necrosis
            Serial sectioning of ipsilateral axillary lym-
phnodes
            Microvessels density
            Peritumoral lymphatic vessel invasion
         Biologic
            Hormonal receptor
               ER
               PR
            Proliferative capacity
               Thymidine labeling index
               S-phase fraction
               Ploidy
            Oncogene expression
               C-myc
               P53
               Her2/neu
*
CONCEPT Primary tumor prognostic factor
   DESCRIPTION:Prognostic factors related to the primary
tumor. Primary tumor generally refers to the cancer tissue
which has been surgically removed in the first surgical op-
eration.
   SUB TYPE OF:Breast cancer prognostic factor
END CONCEPT Primary tumor prognostic factor
Concept
*
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CONCEPT  Brca-1
   DESCRIPTION:a gene whose mutation is related to the he-
redity of breast cancer. A gene is a unit in a
chromosome which controls heredity.
               (chromosome 17q21)
   SOURCES    :Science 266(5182):66-71,1994
   SUB TYPE OF:Tumor related prognostic factor
   PROPERTIES:
      status:{positive,negative}
   AXIOMS:
      positive : germ-line mutation=on





   DESCRIPTION:a gene whose mutation is related to the he-
redity of breast cancer. A gene is a unit in a
chromosome which controls heredity.
               (chromosome 13q12-13)
   SOURCES    :Science 266(5182):66-71,1994
   SUB TYPE OF:Tumor related prognostic factor
   PROPERTIES:
      status:{positive,negative};
   AXIOMS:
      positive : germ-line mutation=on
      negative : germ-line mutation=off
END CONCEPT  Brca-2
Concept
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END CONCEPT  Hormonal therapy
Concept
*
CONCEPT  Other therapy
   DESCRIPTION:
   SOURCES    :
   SUB TYPE OF:  Therapy prognostic factor
   PROPERTIES:
       status:{positive,negative};
END CONCEPT  Other therapy
Concept
*
CONCEPT Breast cancer prognostic factor
   DESCRIPTION:Prognostic factors which refers to the dis-
ease in itself.
   SUB TYPE OF:Prognostic factor
END CONCEPT Breast cancer prognostic factor
Concept
*
CONCEPT Tumor-related prognostic factor
   DESCRIPTION:Prognostic factors which are related to can-
cer itself but not to the cancer tissue.
   SUB TYPE OF:Breast cancer prognostic factor
END CONCEPT Tumor related prognostic factor
Concept
*
CONCEPT Recurrent tumor prognostic factor
   DESCRIPTION:Prognostic factors which are related to the
                recurrent tumor; generally the recurrence of
                a secondary tumor (not metastasis) does not
affect survival in prognosis.
   SUB TYPE OF:Breast cancer prognostic factor
END CONCEPT Recurrent tumor prognostic factor
Concept
*
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       SUB TYPE OF: Therapy prognostic factor
       PROPERTIES:
          status:{positive,negative};
          cycle: {1, 2 ... n};
          drug: NOMINAL;
          quantity: REAL mg;
          frequence: {1,2 ... n weeks};
          date: DATE;
          elapsed time: {1,2 .... n days};




   DESCRIPTION: It is a therapy which focuses on the use of
                X-rays, in order to produce a biologic action
on the human tissue, which can be selective since the tissue
cells are characterised by a different radiosensitivity ac-
cording to their activity and their development stadium.
   SOURCES    :G.Bonadonna, Breast neoplasia
   SUB TYPE OF: therapy prognostic factor
   PROPERTIES:
        status:{positive,negative};
        cycle: {1, 2 ... n};
        drug: NOMINAL;
        power: REAL Gy;
        frequence: {1,2 ... n weeks};
        target: NOMINAL;
        date: DATE;
        elapsed time: {1,2 .... n days};
END CONCEPT  Radiotherapy
Concept
*
CONCEPT  Hormonal therapy
   DESCRIPTION: It is a therapy which focuses on the use of
                hormones; thias therapy was the only treatment
before chemotherapy and radiotherapy were available.
   SOURCES    :G.Bonadonna, Breast neoplasia
   SUB TYPE OF:  Therapy prognostic factor
   PROPERTIES:
        status:{positive,negative};
        cycle: {1, 2 ... n};
        drug: NOMINAL;
        dose: REAL;
        frequence: {1,2 ... n weeks};
        date: DATE;
        elapsed time: {1,2 .... n days};
46 Roberto Sacile
      date: DATE;
END CONCEPT Blood transfusion
Concept
*
CONCEPT Relative with breast cancer
   DESCRIPTION:relatives of the patient who are/were
               breast cancer affected
   SOURCES    :G.Bonadonna, Breast neoplasia:649-651
   PROPERTIES:
      level:INTEGER-RANGE(0-infinite)
   SUB TYPE OF:External factor
END CONCEPT Relative with breast cancer
Concept
*
CONCEPT Therapy prognostic factor
   DESCRIPTION:the treatment which is given to the patient
is obviously one of the most important
               prognostic factor
   SOURCES    :G.Bonadonna, Breast neoplasia
   SUB TYPE OF: Prognostic factor
END CONCEPT Therapy prognostic factor
Concept
*
CONCEPT Surgical  operation
   DESCRIPTION:Surgical operation already undergone
               by the patient
   SOURCES    :G.Bonadonna, Breast neoplasia
   PROPERTIES:
      status:{positive,negative};
      recorrunces:{0,1,... n};
      technique: {mastectomy, lampectomy, quadrantectomy}
   SUB TYPE OF: Therapy prognostic factor




   DESCRIPTION: It is a therapy which focuses on the use of
chemical drugs to treat diseases, specifically cancers.
Chemotherapy is characterised by a chemotherapy index,
which is obtained by the maximum toleration dose and the
minimum curative dose ratio.
   SOURCES    :G.Bonadonna, Breast neoplasia
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                        - more than 25 year-old.
                        - more than 30 year-old.
   SOURCES    :G.Bonadonna, Breast neoplasia:649-651
   SUB TYPE OF:Physic characteristic
   PROPERTIES:





   DESCRIPTION:race of the patient
   SOURCES    :Journal of the National Cancer Institute
               81(24):1879-1886,1989
   SUB TYPE OF:Physic characteristic
   PROPERTIES:





   DESCRIPTION:process for which harmful stimula produce a
collection of reactive modifications of defence in the or-
ganism in order to annihilate them.This reponse is princi-
pally based on the action of the hormones produced in the
cortex part of the surkidney gland. If this action lasts
longtime, this may cause the «general syndrome of adapta-
tion».
   SUB TYPE OF:External factor
   PROPERTIES:





   DESCRIPTION:therapeutic process which consists of
               the introduction in the circulation system
               of a certain amount of blood which has
               been taken from another fellow.
   SOURCES    :Surgery 106(5):836-841,1989
   SUB TYPE OF:External factor
   PROPERTIES:
      status:{positive,negative};
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   DESCRIPTION:time when a woman ceases to menstruate, usu
ally around the age (45,50)
   SOURCES    :G.Bonadonna, Breast neoplasia:649-651
   SUB TYPE OF:Physic characteristic
   PROPERTIES:





   DESCRIPTION:the patients who weights too much
               may have a worst prognosis
   SOURCES    :Annals of Internal Medicine 120(1):18-25,1994
   SUB TYPE OF:Physic characteristic
   PROPERTIES:





   DESCRIPTION:general health assessed by a specialistic
visit
   SUB TYPE OF:Physic characteristic
   PROPERTIES:
      status:{good,bad};




   DESCRIPTION:pregnancy
               null:the patient has never had labour;
               first term pregnancy:
               two groups:
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CONCEPT Prognostic factor
   DESCRIPTION:Factors which allow to predict
                the course of the disease
END CONCEPT Prognostic factor
Concept
*
CONCEPT Patient prognostic factor
   DESCRIPTION:Prognostic factors dealing with the
                host (patient) characteristics
   SUB TYPE OF:Prognostic factor




   DESCRIPTION:Prognostic factors external to the host
   SUB TYPE OF:Patient prognostic factor




   DESCRIPTION:Prognostic factors dealing with the
                physic characteristics of the host. In general,
                as a latest results, these characteristics
are not very related with prognosis, but
may be very related to the risk factors to
become ill.
   SUB TYPE OF:Patient prognostic factor




   DESCRIPTION:the age of the patient is related to prog-
nosis;specifically, prognosis in patients aged
(0, 33) is usually worst; this is due to the
greater frequence of positive axillary lymph
nodes and high proliferative index cases.
   SOURCES    :Lancet 341(8852):1039-1043,1993
   SUB TYPE OF:Physic characteristic
   PROPERTIES:
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7 Appendix B: the CommonKADS domain model for
breast cancer prognosis
In this first part of our approach to the CommonKADS, we have obviously fo-
cused more on the domain knowledge. In this Appendix the last version of the do-
main knowledge is presented. In order to give a more structurated version of the do-
main model, an HTML version is available in http://www.inria.fr/acacia/personnel/
rsacile/roberto.html.




   prognostic factor
      Patient prognostic factor
         Physic characteristic
            Age
            Menopause
            General health
            Overweight
            Pregnancy
            Race
         External factor
            Stress
            Relative
            Blood transfusion
      Therapy prognostic factor
         Surgical operation
         Chemotherapy
         Radiotherapy
         Hormonal therapy
         Other therapy
      Breast cancer prognostic factor
         Tumor-related prognostic factor
            Brca-1
            Brca-2
         Primary tumor prognostic factor
         Recurrent tumor prognostic factor
*
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• biochemical test for liver function before starting adjuvant chemo-
therapy and after the third cycle.
At completion of adjuvant chemotherapy
• repeat biochemical tests if adjuvant chemotherapy is delivered for
more than 3 cycles
• gynecological work-up with pelvic u.s. before starting tamoxifen.
Two months after completion of adjuvant chemotherapy + breast irradiation
- physical examination
- chest X-ray
- mammography (bilateral if conserving surgery)
- cardiac work-up (examination plus ECG)
- biochemical test if not performed at completion of adjuvant chemotherapy.
During the first five years from surgery (in the absence of suspicious findings)
- bone scan after 6 months from completion of adjuvant chemotherapy
- every 6 months
- physical examination





- mammography (bilateral, if conserving surgery)
- ECG
- gynecologic examination plus pelvic ultrasounds (up to the first two years-
from completion of tamoxifen)
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In all patients subjected to adjuvant CMF, Tamoxifen will be delivered at the
dose of 20mg/day for 5 consecutive years, starting at the end of CMF.
In all patients subjected to conservative surgery followed by postoperative
CMF, breast irradiation (max 60 Gy) will be delivered at the end of chemotherapy,
either concomitantly or before tamoxifen.
ADJUVANT CHEMOTHERAPY IN OPERABLE BREAST CANCER IN WOM-
EN NOT SUBJECTED TO PRIMARY CHEMOTHERAPY
At surgery: FULL AXILLARY DISSECTION, TUMOR GRADE, CELL PROLIF-
ERATIVE ACTIVITY, ESTROGEN RECEPTORS
Within 14 days after surgery
• if N- and POSITIVE ER and LOW PROLIFERATIVE ACTIVITY andDIFFER-
ENTIATED TUMOR (variables measured at diagnosis and at major surgery)
NO SYSTEMIC THERAPY
BREAST IRRADIATION (max 60 Gy) AFTER CONSERVATIVE SURGERY
• if N- and NEGATIVE ER or HIGH PROLIFERATIVE ACTIVITY or UNDIF-
FERENTIATED TUMOR (variables measured at diagnosis and atmajor sur-
gery)
ADJUVANT CMF (C 600 mg/m2 , M 40 mg/m2 i, F 600 mg/m2 , days 1 and 8,
iv q. 4 weeks) for 3 or 6 cycles
• if N+ 1 to 3, regardless of other variables
ADJUVANT CMF as above
• if N+ > 3, regardless of other variables
ADJUVANT CMF (same dose and schedule) for 6 cycles.
FOLLOW-UP STUDIES
During adjuvant chemotherapy administration:
• complete blood counts with differential and platelets before each iv
administration
• physical examination before starting any new cycle
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    FINE NEEDLE ASPIRATION (cell diagnosis, ER-ICA, PgR-ICA,
Ki-67, nuclear grade)
Within 7 days from mammography:
- Day1Epirubicin 120 mg/m2 iv
- Day22Epirubicin 120 mg/m2 iv
- Day43Epirubicin 120 mg/m2 iv
- Day63Repeat mammography, breast u.s., chest x-ray
- Day64SURGERY
• if at operating room T ≤ 2.5 - 3 cm, no scattered foci outside quadrant area:
CONSERVATIVE SURGERY
• if at operating room AT > 3 cm, or scattered foci outside quadrant area:
MASTECTOMY
For both technical procedures: FULL AXILLARY DISSECTION, TUMOR
GRADE, CELL PROLIFERATIVE ACTIVITY, ESTROGEN RECEPTORS
Within 14 days after surgery
• if N- and POSITIVE ER and LOW PROLIFERATIVE ACTIVITY and DIFFER-
ENTIATED TUMOR (variables measured at diagnosis and at major surgery)
NO SYSTEMIC THERAPY
BREAST IRRADIATION (max 60 Gy) AFTER CONSERVATIVE SURGERY
• if N- and NEGATIVE ER or HIGH PROLIFERATIVE ACTIVITY or UNDIF-
FERENTIATED TUMOR (variables measured at diagnosis and at major sur-
gery)
ADJUVANT CMF (C 600 mg/m2 , M 40 mg/m2 i, F 600 mg/m2 , days 1 and 8,
iv q. 4 weeks) for 3 or 6 cycles
• if N+ 1 to 3, regardless of other variables
ADJUVANT CMF as above
• if N+ > 3, regardless of other variables
ADJUVANT CMF (same dose and schedule) for 6 cycles
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If axillary nodes are histologically negative (or if surgery has not been per-
formed) consider other variables determined either at diagnosis or at surgery:
• if NEGATIVE ESTROGEN RECEPTOR or HIGH PROLIFERA-
TIVE ACTIVITY or UNDIFFERENTIATED TUMOR
adjuvant chemotherapy should be delivered. A non-cross resistant
adjuvant regimen is highly advisable (e.g. CMF days 1 and 8 q. 4
weeks for 3 or 6 cycles);
• if POSITIVE ESTROGEN RECEPTOR and LOW PROLIFERA-
TIVE ACTIVITY and DIFFERENTIATED TUMOR
no adjuvant systemic therapy should be delivered.
In patients subjected to adjuvant chemotherapy, tamoxifen can be delivered at
the dose of 20 mg/day for 5 consecutive years, starting at the end of adjuvant chem-
otherapy.
In all patients subjected to conservative surgery, breast irradiation (max 60
Gy) will be delivered. When adjuvant chemotherapy is planned, breast irraA concep-
tual information retrieval system for the production
of guidelines on prognostic factors of breast cancerA conceptual information retriev-
al system for the production
of guidelines on prognostic factors of breast cancerA conceptual information retriev-
al system for the production
of guidelines on prognostic factors of breast cancerdiation should be started at the
end of chemotherapy to avoid dose-intensity reductions.
PRIMARY CHEMOTHERAPY IN OPERABLE BREAST CANCER
OPERATIONAL FLOW
At palpation: T>2.5 cm, N0-2, M0
1) MAMMOGRAPHY
if T ≤ 2.5 cm --> conservative approach
if T> 2.5 cm
2) BREAST U.S.
    TATTOO OF BREAST LESION
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• PERFORM FINE NEEDLE ASPIRATION with sufficient material
to allow determination of
- cell diagnosis (malignant cells must be documented
prior to start chemotherapy)
- nuclear grade, estrogen and progesterone receptors
with immunocytochemistry, cell proliferation activity
(primary chemotherapy can achieve pathologic com-
plete remission of the tumor and knowing about these
variables can allow to assess whether patients need
postoperative systemic treatment).
b. Within 7 days from diagnosis: start primary chemotherapy (e.g. epirubicin
120 mg/m2 iv q.3 weeks for 3 cycles)
c. Within 3 weeks from the end of primary chemotherapy: repeat mammogra-
phy and breast ultrasounds and compare imagins with those performed at diagnosis.
• if primary tumor measures <2.5 cm and no scattered foci at distance,
consider conservative approach (e.g. quadrantectomy or lumpecto-
my with full axillary dissection)
• if primary tumor measures >3cm or scattered foci at distance are
present, consider modified radical mastectomy with full axillary dis-
section
SURGERY (conservative or radical) must be performed within 3 weeks from
the last dose of primary chemotherapy.
At surgery, if residual tumor is present in adequate quantity, tumor grade, cell
proliferative activity and steroid receptors must be determined.
Within 14 days from surgery, postoperative systemic treatment, if needed,
should be started.
In the presence of positive axillary nodes, postoperative chemotherapy should
be delivered regardless of other prognostic variables and degree of primary tumor re-
duction. A non-cross resistant adjuvant regimen is highly advisable (e.g. CMF i.v.
days 1 and 8 q. 4 weeks for 6 cycles).
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6 Appendix A: skeleton of a guideline commonly used for
breast cancer treatment in Italy
The following documents are in relation to the operational procedures in two
"protocols" for breast cancer treatment, one for primary chemotherapy and the sec-
ond for adjuvant chemotherapy.
The following is copy as written by oncologists.
MULTIDISCIPLINARY TREATMENT IN OPERABLE BREAST
CANCER
a. At mammography:
- if, regardless of primary tumor diameters, scattered foci are present outside
a quadrant; consider conventional surgical approach (e.g. modified radical mastecto-
my with full axillary dissection);
- if maximum tumor diameter is < 2.5 cm and no scattered foci at distance:
consider conservative approach (e.g. quadrantectomy or lumpectomy with full axil-
lary dissection + breast irradiation);
- if maximum tumor diameter is > 2.5 cm and no scattered foci at distance;
consider primary chemotherapy to facilitate conservative approach and reduce the
risk of local recurrence.
PRIMARY CHEMOTHERAPY IN OPERABLE BREAST CANCER
a. Following mammography and breast ultrasound:
• TATTOO OF BREAST LESION (primary chemotherapy can reduce
the size of the primary and thus will facilitate surgeons to consider
initial shape of the primary)
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ified, as well its reliability (in this case also the term “axiom” should be revised); the
introduction of some kind of function should be allowed to avoid long lists of similar
axioms, like in TNM_stage. The task knowledge does not provide any representation
to decompose tasks in sub-tasks which are not sequential; such as, for example, in
the prognostic task, it is not easy to represent the assessment deriving from literature
consultation, even if this updating is intrinsic to a possible model of a human expert
in oncology.
In conclusion, although the work presented here may be interpreted just as an
exercise of CommonKADS application in the medical domain, the conceptual model
we have obtained seems to reflect well the new trends of breast cancer prognosis; be-
sides, we are still far from a design model of the prognostic system, and from verify-
ing the gap between conceptual and design model which has been addressed in[19]
as one of the worse features of KADS-I methodology. From this experience, we can
conclude that CommonKADS has been a good support for conceptualisation, al-
though its standardisation process has not finished yet, and a standard, leading tool
is needed to support it.
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The guideline (GL) database is the real core of the system; specifically its for-
malism as well as its level of abstraction has to be defined in order to comply a trade-
off between natural language and computer language structure. The need of a repre-
sentation which is not distant from the natural language is due to the very fact that a
guideline should always have a correspondant in natural language (a sort of guideline
“book”). Besides, it is feasible that in the next few years multimedia and/or network-
ing techniques will be used to describe guidelines; in this case, although guidelines
are still expressed in natural language, a greater effort in structuring the GL contents
will be performed. Finally, guidelines might become object of the inferring of knowl-
edge based systems (KBS) as well as of other applications, so in this case GLs should
be expressed in a language which is highly structured in order to infer on it and to
allow a fast access to a specific content; moreover a highly structured language will
be necessary to automatate the guideline building process. CML may be a good can-
didate for this representation.
4.2 Conclusions
Our conclusion is that CommonKADS was a satisfactory methodology to con-
ceptualise prognosis, since it guided us to approach the problem in a structured way;
first, we decomposed the prognostic task into subtasks which were already defined
in the CommonKADS library; subsequently, we defined the domain knowledge in-
volved, following CML; then we defined the inference layer following the library,
and finally we defined the task knowledge. Following this conceptualisation, we
have found a significant help; specifically, exploding the prognostic process has al-
lowed us to find a problem definition which fits well the needs of a modern definition
of prognosis, and which can reuse the models already developed in the library; the
domain knowledge and its CML definition allows a good definition of a glossary of
the terminology used and it is also a good way to approach knowledge acquisition
both from literature and from human experts; in the latter case, CML has been found
an easy language to have a dialogue with experts, who could directly evaluate the ev-
olution of the work. The inference knowledge and the task knowledge have given us
a trace of models that can be reusable for our aim.
On the other hand, CommonKADS is not a cookbook for building expert sys-
tems[19], yet. The research in the CommonKADS library of generic models is not
easy, since some models have not been developed to a great extent (i.e. the qualita-
tive model); in some cases (i.e. prediction model) the reader has to refer to the work
done in previous releases (KADS-I) thus facing in changes of terms and approaches.
Besides, the CML is commonly used in a grammar that is more practical in some as-
pects than the one we have referred to; in our opinion, further work is needed also in
CML; for example, concept and relation axioms are a central issue in modelling a do-
main when starting from a knowledge acquisition process and their role should be
stressed and deeply formalised; for example, the source of an axiom should be spec-
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Figure 11 : A guideline system architecture.
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In this respect, the results of the knowledge acquisition process may be viewed
as a guidelines (GL) database which can be used to produce guidelines as well as to
be accessed by computers applications (see fig.10).
With respect to GL productions, a system which guides the conceptualisation
of the knowledge contained in a paper should represent a valid help in the production
of a guideline. In a future development of this work, the definition of a conceptual
information retrieval system for the production of guidelines on prognostic factors of
breast cancer should be also addressed.
There are several medical models that have been implemented which address
different aspects of this domain, such as, for example, ICD9 (International Classifi-
cation of Diseases with Clinical Modifications), GMN (Gabrieli Medical Nomencla-
ture) and GALEN (Generalized Architecture for Languages, Encyclopaedias and
Nomenclatures in Medicine).
A possible architecture of the global system we propose is shown in fig.11. We
propose a four-layered architecture. The text processing layer processes the informa-
tion source (IS) database in order to select the papers which contain the topics ad-
dressed by the guideline. This can be performed by a traditional information retrieval
(IR) system which can select from IS the papers which address a specific topic (mod-
elled in an IS model, in the form of boolean expressions of keywords). The service
given to the upper layer is a queue of papers which satisfy the information needs of
the addressed GL modelled in the IS model.
The assessment layer performs the conceptualisation of the papers selected at
the text processing layer. Each selected paper is abstracted and compared with an IS
conceptual model, which defines the syntax, the relations and the constraints of the
concepts which should be contained in the current selected paper in an abstract for-
malism. The services provided to the upper layer is the result of this comparison,
which is assessed in a decision which contains the abstracted structure of the selected
paper as well as parameters indicating its compliance with quality criteria.
The learning layer stores the decisions given from the assessment layer. The
service of this layer is to update the guideline. An assessment task compares the GL
database with each element of the queue; the result of the assessment may be either
an updating of the GL database with the results presented in the paper or a decision
of not taking into account those results.
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4 Future developments and conclusions
4.1 A conceptual information retrieval system for the production
of guidelines on prognostic factors of breast cancer
The first steps of a guideline production are the reading of the literature on a
specific topic, the conceptualisation and the understanding of it, and the assessment
whether the concepts contained in it are proper to be added or to modify the guide-
lines which concern this topic (such as, for example, according to criteria about the
quality of the research). The key point of this process is the knowledge conceptuali-
sation and the result understanding.
Figure 10 : A guideline database containing the conceptual structure
of the breast cancer prognosis (and therapy) domain should have differ-
ent applications, such as, for ex. the production of guidelines, the con-













3.4 A simplified model for breast cancer treatment in CML
One of the main problems of actual release of CommonKADS methodology
is that it lacks of a standard, leading tool which can guide the user in the application
of the whole methodology. Other methodology, such as Protege from Stanford Uni-
versity, do not have this problem since the methodology has followed the evolution
of a related software tool.
For CommonKADS, the KADS_tool is one of the best known tools to use
CommonKADS, but it presents many features from KADS-I which has been over-
come in CommonKADS.
It is the author’s opinion that a CommonKADS-dedicated tool should be
strictly adherent to the CommonKADS standard and, first of all, to CML, the con-
ceptual modelling language which has been reccomended to CommonKADS.
The KACTUS toolkit, by the University of Amsterdam and Cap Programator
(Stockholm), supports CML. KACTUS is an interactive environment for browsing,
editing and managing (libraries of) ontologies. The toolkit is currently under devel-
opment. One of the aims of KACTUS is to support reuse of ontologies, in other to
support this, the toolkit can handle various ontology formalisms (CML, EXPRESS
and Ontolingua) and can perform (partial) translations between these formalisms.
Specifically, in the group ACACIA, a CML-supporting tool, COKACE (Com-
monKADS Centaur) is under development. This tool has been developed with the
CENTAUR environment, also developed at INRIA. COKACE, allows to develop a
CML model according to the CML standard definition, to check its consistency and
to interpret it. Since a first version of the tool has been available in these last few
days, and anyway it is always better to test tools on easier examples, a simplified ex-
ample of the breast cancer prognostic problem has been developed. In this example,
some factors have been regarded as a biological manifestation; this biological mani-
festation can produce risk factors. The combination of risk factors produced as well
as risk factors given as user input, can produce a risk as a result, which may assume
the high value and the low value. In section8 page 72 (Appendix C), this model has
been reported.
Obviously, the advantage of using a tool is that it constrains the knowledge en-
gineer to a more realistic version of its conceptual model. Besides, the risk of a tool
very related to a language is to become nothing but a shell for software production.
It is the author’s opinion, that to overcome this risk, the next step to be performed in
the COKACE tool, is to give the user a collection of reusable models (specifically,
inference and task knowledge) to be «cut & pasted» in the user application.




GOAL:  to predict the evolution of breast cancer (bc) dis-
ease at least in terms of survival and disease-free time
INPUT:
prognostic factors: the set of prognostic factors about bc
in a patient model description: set of parameter/value
pairs to define a partial bc description
therapy: previous, actual and proposed therapy for that bc
OUTPUT:
evolution of the disease: survival time, disease free, re-
currences ....




sub-taskS: bc_assess, bc_update, bc_predict
ADDITIONAL-ROLES:
decision: a set of data, referring to the input prognostic
factor,for ex., the value of the prognostic factor, if the
procedures to determine it were fitted to guidelines,
whether considering or not this prognostic factor...
model of prognostic factors: abstracted guideline on prog-
nostic factors
model description: description of bc on which evolution
should be predicted
CONTROL-STRUCTURE:
bc_prognosis ( prognostic factors + model description +
therapy → evolution + messages) =
REPEAT
; assess the value and reliability of a specified prognos-
tic factor
bc_assess (prognostic factor + model of prognostic factors
→ decision);
UNTIL there are any input specification for prognostic fac-
tors
; update the model description, both from input description
and from decisions
bc_update (model description + decision → model descrip-
tion)
; predict the evolution of bc, thus predicting also evolu-
tion and giving control messages
bc_predict (model description → model description + evolu-
tion + messages);
END TASK bc_prognosis
Figure 9 : The task knowledge of the prognostic system.
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Starting from this, past states (A, B) and future states (D, E) should be predict-
ed, thus defining the track (A, B, C, D, E). The choice of the proper therapy will come
from this track definition.
In this case, the addition of information from literature to the system should
not need a reinterpretation of the qualitative model or of the assessment model, but
an upgrade of the primitive inferences.
3.3.5. The task knowledge
Oncology is perhaps one of the more knowledge structurated domain of med-
icine, in which task as diagnosis, assessment, scheduling are continuously studied
and applied.
Specifically, the primitive task knowledge involved in prognosis are assess-
ment and prediction (as defined by fig2d); fig.9 shows the root task knowledge of the
prognostic task, which can be decomposed in an assessment, a prediction and an up-
dating task. As refers to assessment and prediction task, their refinement reflects the
correspondent CommonKADS library of generic models, while the updating task is
just a combination of “specify” inferences on the system model.
Besides, when dealing with task knowledge, we should focus on two separate
modules: an assessment task for the updating of the prognostic system from literature
and the prognostic system itself composed by assessment and prediction. The con-
nection between these two modules is not really straightforward; in the sense that up-
dating may depend on prognosis, but it can also “run” independently, that is when
some “stimulus” is present. Some techniques currently not provided by Com-
monKADS should be needed to solve the problem; fig.9 does not take into account
the updating from literature.
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In theory, the addition to the system of information from literature should not
need a reinterpretation of the domain, if a good work of abstraction has been done in
considering all the possible classes of prognostic factors and the possible influences
on the behaviour of the tasks. As an easy example, if the HER2 prognostic factor
were not included in the model, its super-concept “oncogene” must be present, thus
allowing a new instantiation of it, as well as of the referring axioms. In the case a
prognostic factor is already present, but a different (or in agreement) interpretation
is given from literature, the system should “properly” update the axioms and the re-
lations involved. In section 7 page 43 (Appendix B), the skeleton of the domain
knowledge of breast cancer prognosis is shown. This information can be easily read
by consulting http://www.inria.fr/acacia/personnel/rsacile/roberto.html.
3.3.4. The inference knowledge
The inference structure (fig.7) reflects the prediction inference knowledge by
[21], the assessment inference knowledge by [16, chap.7]; and the preliminary defi-
nition of the assignment inference knowledge by [16, chap.11]. Besides, following
the CommonKADS library of generic models, we should have a guide to describe
our conceptual model in more detail.
Prognosis is in the middle layer of fig.7, that is an assessment task on prognos-
tic factors of the patient and a prediction task of breast cancer behaviour; the assess-
ment on prognostic factors extracted from literature is in the lower layer, while ther-
apy is in the upper layer. The system model of prognostic factor is a static role when
referred by prognosis, but it can be updated by the assessment on information source.
The prediction is strongly related to the development of a qualitative model of breast
cancer, since the relations and the parameters in this domain are “naturally” qualita-
tive rather than quantitative; this model is currently being in phase of development,
following [21, 22] and some specific previous work [23, 24]. The transition between
one state and another of the qualitative model is determined both by the biological
features of the tumour and by the values of prognostic factors, including therapy. The
qualitative model should predict the future state (and the therapy will be the variable
that should optimise prognosis) as well as the past states (identified also by other pre-
vious information, such as for example, the clinical card of the patient). The identi-
fication of the past states will be used for a better identification of the track corre-
sponding to the tumour evolution (fig.8), and, as a consequence, to an improved def-
inition of the current stage. A qualitative model of breast cancer should cover the
prognostic space with states and transitions. Nowadays, prognosis is not only the re-
sult of an assessed stage of the disease, but it may be regarded as the research in the
prognostic space (defined as “disease evolution x elapsed times” from the cancer
birth) of the evolution track related to the current patient. As a first step, prognosis
should consist of assessing breast cancer stage and prognostic factors; this should de-
fine probable milestones of the track (fig.8b, C, C’).
22 Roberto Sacile
CONCEPT TNM_stage
DESCRIPTION: “This staging system provides a strategy for
grouping patients with respect to prognosis.  Therapeutic
decisions are formulated in part according to staging cat-
egories but primarily according to lymph node status, ER
and PR receptor levels in the tumour tissue, menopausal
status, and the general health of the patient. TNM stages
are defined by primary tumour (T), regional lymph nodes
(N) and pathologic classification (pN), distant metastasis
(M).”
SOURCES: 1. Breast.  In: American Joint Committee on Can-
cer: Manual for Staging of Cancer. Philadelphia: JB Lip-
pincott Company, 4th ed., 1992, pp 149-154.









∀ T:size N:axillary_node M:metastasis TNM:TNM_stage
has_status(T, Tis) ∧ has_status(N, N0) ∧ has_status(M, M0)
→ has_status (TNM, 0);
has_status(T, T1) ∧ has_status(N, N0) ∧ has_status(M, M0)
→ has_status(TNM, I);
(has_status(T, T0) ∧ has_status(N, N1) ∧ has_status(M, M0)) ∨
(has_status(T, T1) ∧ has_status(N, N1) ∧ has_status(M, M0)) ∨
(has_status(T, T2) ∧ has_status(N, N0) ∧ has_status(M, M0))
→ has_status(TNM, IIA);
(has_status(T, T2) ∧ has_status(N, N1) ∧ has_status(M, M0)) ∨
(has_status(T, T3) ∧ has_status(N, N0) ∧ has_status(M, M0))
→ has_status(TNM, IIB);
(has_status(T, T0) ∧ has_status (N, N2) ∧ has_status (M, M0)) ∨
(has_status(T, T1) ∧ has_status (N, N2) ∧ has_status (M, M0)) ∨
(has_status(T, T2) ∧ has_status (N, N2) ∧ has_status (M, M0)) ∨
(has_status(T, T3) ∧ has_status (N, N1) ∧ has_status (M, M0)) ∨
(has_status(T, T3) ∧ has_status (N, N2) ∧ has_status (M, M0))
→ has_status (TNM, IIIA);
(has_status (T, T4) ∧ has_status (M, M0)) ∨
(has_status (N, N3) ∧ has_status (M, M0))
→ has_status (TNM, IIIB);
has_status (M, M1)
→ has_status (TNM, IV);
END CONCEPT TNM_stage
FIGURE 6
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CONCEPT HER2
DESCRIPTION:  “a proto-oncogene whose overexpression is
likely to have a direct impact on cellular growth control
and to the aggressiveness of the tumour.”
SYNONYMS: erbB-2; HER2/neu
SOURCES: 1. Bacus S., Zelnick C., Plowman G. and Yarden Y.
“Expression of the erbB-2 family of growth factor recep-












DESCRIPTION: “Paraffin sections are cut from tissue blocks
on poly-L-lysine coated slides. After the sections are de-
waxed and rehydrated, they are treated with 0.1% protease
for 20 minutes at 20˚C to  22˚C. This is followed by in-
cubation with a mouse monoclonal antibody (4 mg/mL over-
night at 4˚C) to the external domain of the HER-2 protein.
Bound antibodies are demonstrated by the avin-biotin-per-
oxidase sequence. The sections are counterstained with me-
thyl green.”
SOURCES: 1. Toikkanen S. et al.. “Prognostic significance
of HER-2 oncoprotein expression in breast cancer: a 30-
year follow-up”.........
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port, etc.; so, it should also be assessed whether it is worthwhile to add the knowl-
edge deriving from this article to the assessment and prediction system models in or-
der to improve the prognostic judgement and, as a consequence, a proper therapy.
This assessment task does not take part of the chain of the expert tasks for patient
management; it is in a certain way an optional task (a task in which the whole system
is updated), or a task which is performed “now and again”, that is at sample periods
or when a case needs a better evaluation.
In conclusion, we regard patient management as the collection of tasks of
fig.2d (like in [16, chap.4], this chain, as well as the previous ones, reflects depend-
encies not an order of processing). This collection corresponds to 1) diagnosis, 2)
prognosis 3) selection of therapy, 4) follow-up. The aim of our conceptualisation is
2).
After having defined the generic models which should be suited to our prob-
lem, we can conceptualise it; the CommonKADS conceptualisation of the breast
cancer prognosis should be in terms, at least, of a description of the domain, infer-
ence and task knowledge involved in the problem.
3.3.3. The domain knowledge
Within the domain knowledge, we construct the axiomatic structure; this
takes the form of producing a domain lexicon and a concept hierarchy. With respect
to this and to our data sources, we have defined a hierarchy of ontologies [18]; fig.3
shows the root schema of the domain level; fig.4 shows the domain knowledge of
the prognostic problem. As regards concepts, we have defined seven “primitive”
concepts, that are: patient, breast cancer, information source, prognostic factor,
prognosis, therapy and laboratory test (general, prognostic and therapy). Fig. 5 and
6 show the “is-a” concept hierarchy for the “prognostic factor” and for “primary tu-
mour prognostic factor” concepts; fig.7 shows an example of definition of a prog-
nostic factor (the HER2 growth factor receptor), of the related laboratory test (the
immunoperoxidase test) and of the TNM stage. In TNM stage, an example of axioms
appears.
In the following pages:
Figure 4 : The “is-a” hierarchy for the prognostic factor concept.
Figure 5 : The “is-a” hierarchy for the primary tumour prognostic fac-
tor concept
Figure 6 : Three examples of concept “leaves” of the concept hierar-
chy: the HER2 proto-oncogene, the Immunoperoxidase laboratory test
and the TNM stage.
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on whether we are looking for current properties of the breast cancer or whether we
want to identify currently not observable states (i.e. past, present and future biolog-
ical growing characteristics) of the breast cancer; in the first case, we should ana-
lyse breast cancer factors and determine a “stage” that is known to lead to a certain
evolution of the disease; in the second case we should determine biological breast
cancer history and evolution, by modelling the tumour activity and observing the
biological characteristics of the disease. The first case corresponds to the task usu-
ally performed by oncologists during their work; the second case is the task more
usually performed by researchers in cancer biology. The modern view of oncology
joins the two cases, since nowadays the biological history of the tumour is more
taken into account and prognosis is the consequence of analysing the interactions
among “classical” prognostic parameters in relation to the biological activity of the
tumour.
In the first case, following the cycle of patient management specified above
and the suite of problem types in [16, chap.4], the management of breast cancer pa-
tient is the sequence of tasks shown in fig.2b. Connecting fig.2a and fig.2b, diag-
nosis includes initial diagnosis and its confirmation, assessment includes the eval-
uation of the disease (that is the stage considering certain prognostic factors and the
associated prognosis), assignment includes the selection of therapy and monitoring
includes the follow-up of the patient. With respect to this, prognosis is well distin-
guished from diagnosis: diagnosis is the task which establishes the presence or ab-
sence of the disease, while assessment determines its grade (stage) attribution. This
parallels the approach normally adopted in clinical practice, in which normally the
first step is diagnosis, and subsequently prognosis follows, possibly after further
examinations. Moreover, monitoring is included in follow-up and it is not needed
properly in prognosis; while prediction is not needed since the current stage of the
disease (as well as a certain memory of the previously assessed ones) determines
the proper therapy.
However, if we consider prognosis as a task in which the biological history
of the cancer has to be reconstructed and predicted, the assessment task should be
further specialised by the addition of a prediction task (fig.2c). In this case, the as-
signment of a therapy at a given instant is a parameter of the function which takes
into account the global history - past, present and future - of the tumour (fig. 8). A
proper therapy assignment should optimise the prediction in order to maximise
some output parameter (such as, for example, the survival time); in this case, ther-
apy is not a direct consequence of the stage of the disease, but it comes out from a
sort of “propose and revise” task [16, chap.11], for example, by considering the
identified states of the tumour history as different levels of abstraction of the dis-
ease. This optimization problem is not addressed in this work.
Moreover, diagnosis, prognosis, therapy and follow-up needs including new
reliable research findings, but this is more perceived in prognosis. The knowledge
which should update our guideline system for breast cancer prognosis also comes
from an assessment task; that is, for example, after reading an article on breast can-
cer prognosis, it can be assessed that the presented results are reliable, maybe in
contradiction with previous ones, that other previous results receive further sup-
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Moreover, prognosis is not a task built upon static knowledge. A prognostic
knowledge model should allow updating knowledge, by the introduction of new re-
search results on prognostic factors. In this work, we do not intend to face the con-
ceptualisation of knowledge extraction deeply, since it is anyway a process that is in-
dependent of prognosis, which is the objective of this work. The present model
should be planned in order to allow the introduction of the output of this knowledge
extraction process. So, while we assume that this knowledge extraction process is
feasible (at least it is feasible to select the papers that deal with breast cancer prog-
nosis with the help of a bibliographic research, i.e. by introducing proper keywords
in a CD-ROM), we should provide both a “format” for this knowledge and the mech-
anism to allow for its insertion in the expert model.
Before starting with the description of the knowledge categories of the prog-
nostic problem, it is worthwhile to check whether problem definitions already
present in CommonKADS are also suitable for prognosis, in order to reuse elements
of the CommonKADS modelling libraries that are already potentially modelled for
breast cancer prognosis.
3.3.1. Definition of prognosis
We used the term “prognosis” with the meaning of judgement - assessed by a
physician after a diagnosis - of the duration of a disease and the prediction of its fu-
ture behaviour; in our case, at least in terms of survival time (such as, for example,
5-year and 10-year classes) and tumour recurrence. With respect to this, it is clear
that we are dealing with an analysis problem [16, chap.4], which includes prediction,
monitoring, diagnosis and assessment. Prediction seems the best aspect, since “pre-
diction” is intrinsic to the definition of the problem, that is prognosis as prediction of
the behaviour of the tumour. Anyway also monitoring (since we are interested in an
“on line prognosis”, that is, prognosis of a disease in a patient should be revised in
time, specifically since we are considering long periods), diagnosis (since prognosis
may be regarded as a more detailed diagnosis, that is, after a diagnosis of the disease,
variables such as, for example, survival time should be estimated), and assessment
(since a class/grade of the disease has to be identified) aspects may be considered as
possible candidates for the application of the CommonKADS methodology.
3.3.2. Decomposition of prognosis in generic tasks
In order to identify prognosis tasks, we decomposed patient management in
order to verify whether it consists of a mixture of generic tasks. Since reusability is
also addressed by CommonKADS, we have searched if the subtasks obtained were
already defined in the CommonKADS library.
The prognostic task (“evaluation of the disease” in fig. 2a) is the crucial point
of the patient management. The task definition of the prognostic task mainly depends































Figure 3 : The domain level at the root definition.
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Figure 2 :
(a) Breast cancer patient management.
(b) Transferring of patient management to reusable tasks.
(c) The modern trend of breast cancer oncology, regarding prognosis
not only as a stage assessment, but as a prediction of the biological his-
tory of the tumour.
(d) Updating of (c) tasks should be allowed, by extracting knowledge
from literature, thus introducing an assessment task, which regards all
the tasks of patient management, particularly the prognostic tasks.
 1.initial diagnosis ⇒ 2.confirmation of diagnosis ⇒
 3.evaluation of disease ⇒  4.selection of therapy ⇒ 5. follow up
 
 (a)
     diagnosis → assessment→ assignment → monitoring
(b)
diagnosis → assessment → prediction → assignment → monitoring
(c)
assessment
diagnosis → assessment → prediction → assignment → monitoring
(d)
  1   2   3   4
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• the task knowledge describes a recursive decomposition of a top-level task in sub-
tasks, specifies these tasks, and describes when the subtasks are to be executed in
order to achieve their parent task (control).
These descriptions are made by the CommonKADS Conceptual Modelling
Language (CML) [18]. For many applications, these three layers are sufficient to
build the system. Moreover, the CommonKADS modelling libraries capture knowl-
edge engineering expertise in terms of reusable elements that are potentially mod-
elled in a project. For example, the CommonKADS library of generic models offers
models for diagnosis, design, planning, etc. These descriptions are made through the
CommonKADS Conceptual Modelling Language (CML) [18].
3.2 The sources of experience
In our model, we deal with two types of knowledge:
• well assessed knowledge - which has already been included in prognostic guide-
lines - in order to produce the skeleton of the model for the prediction of the be-
haviour of breast cancer;
• new knowledge - which has not already been included in prognostic guidelines -
in order to add new prognostic factors in the model.
In the first case, we followed the trace and the bibliography of the document
“Breast Cancer” for physicians contained in the CancerNet Web info-server with
PDQ (Physician Data Query) statements from National Cancer Institute USA (avail-
able at http://biomed/nus.sg). In the second case we should consider articles on breast
cancer prognostic parameters taken from specialised journals.
Moreover, experts in oncology from IST (Genoa, Italy) have been consulted
during the modelling construction process.
3.3 The general model
In order to transform the problem into a “well-defined” problem, we must find
out how breast cancer prognosis is inserted in the patient management process. The
management of breast cancer patients generally follows the task flow of fig.2a. In
this work, we focus on the 3rd task. In general, 3rd, 4th and 5th tasks are iterated, that
is the evaluation of the disease may be reassessed during follow-up, and therapy may
be also reassessed in order to allow “ad hoc” changes in the selection of therapy; for
example, after a surgical removal - which might be considered as an optional therapy
(since it is not always necessary, although it is often performed) - an additional eval-
uation of the disease is certainly assessed.
12 Roberto Sacile
3 Modelling breast cancer prognosis and treatment with
CommonKADS
3.1 Conceptual modelling with CommonKADS
Our approach to the conceptualisation of the problem follows the Com-
monKADS (Knowledge Acquisition and Design Structuring) Library for Expertise
Modelling, as described in [16]. KADS is a comprehensive methodology for the de-
velopment of knowledge based systems (KBS); KADS was set up during European
research projects (ESPRIT P1098 and P5248) and is becoming a “de facto” standard
for KBS development in Europe; KADS methodology is currently under evolution
and CommonKADS is the name of the last version which was available at the begin-
ning of this work.
A CommonKADS model is a set of interrelated models from the Com-
monKADS model set. This model set specifies six model templates to describe dif-
ferent views on, or models of, a problem solving context [16]. The six models are:
1. the Organisation Model, which describes the organisational context in which the
knowledge based activities that the project is concerned with occur;
2. the Task Model, which describes the tasks and activities that are executed to re-
alise the organisational function;
3. the Agent Model, which collects the relevant properties of the different agents
performing the previous defined tasks;
4. the Communication model, which describes transactions between agents;
5. the Expertise Model, which describes the knowledge of an agent relevant to a par-
ticular task;
6. the Design Model, which describes the realisation of the problem solving behav-
iours described in the Expertise and Communication models in computational
and representational terms.
In this work we address the CommonKADS Expertise Model. Expertise mod-
elling is founded on the Newell’s notion of knowledge level [17]. In CommonKADS
the different roles are captured in three basic independent knowledge categories [16]:
• the domain knowledge specifies form, structure and contents of the specific do-
main which is relevant for an application (structures described through concepts
and relations);
• the inference knowledge specifies the primitive steps in reasoning (inferences) in
an application and the knowledge roles that refer to classes of domain knowledge
statements manipulated by the inferences;
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Modelling Language) [18] allows a structural approach to conceptualisation. Thus,
in our opinion, it is worthwhile to use CommonKADS for our aim. The model pre-
sented here has been built following CommonKADS methodology according to [16]
and [18]; at this stage, we have not used any specific CommonKADS tool. Later on,
we tested COKACE (CommonKADS-Centaur), a tool developed in the ACACIA
group. This tool supports the building and validation of CommonKADS expertise
models, described in CML. We used this tool for the construction of a simplified
model which regards the treatment of breast cancer; this model has been reported in
section 8 page 72 .
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The aim of this part of work is to provide a preliminary conceptualisation of
the breast cancer prognosis while evaluating the efficacy of the CommonKADS
methodology in facing the problem. In this respect, we wanted to build a conceptual
knowledge model (in CommonKADS referred to as model of expertise) of the breast
cancer prognosis, that is an intermediate knowledge representation understandable
by the human expert and by the knowledge engineer, thus enriching communication
and leading gradually to a shared understanding of the emerging conceptual model
of the domain [8], as well as improving explanation, documentation and maintenance
of the application. The definition of a conceptual knowledge model may be further
used for the development of an expert system on the prognosis of breast cancer; ther-
apy will also be addressed in terms of prognostic factor.
2.3 Related works from bibliography
In literature, there are several examples of expert systems on oncology patient
management and diagnosis, such as, for example, ONCOCIN [9, 10], BREASTCAN
[11], INC2 [12], SENEX [13] and others [14, 15]. Most of them focus on guiding the
treatment of patients according to well assessed protocols, whereas the aim of the
present work focuses on well assessed and new prognostic factors (extracted from re-
cent literature), in order to give a prediction of the behaviour of the tumour which
allows for the administration of an appropriate therapy. In this respect, we are not,
actually, interested in patient management, but rather in producing an “intelligent”
information system, that is a system which is able to inform and guide the physician
in the analysis of recent findings and guidelines on breast cancer prognosis.
KADS has already been used for cancer treatment modelling in K-ONCOCIN
[19] (specifically of Northern California Group Protocol 2083-1 for small-cell lung
carcinoma treatment in ONCOCIN [9, 10]). The results of the application of the
KADS methodology in K-ONCOCIN were not completely satisfactory; for example,
the library of interpretation models (general models in CommonKADS) did not pro-
vide an inference structure that they could have used to model their task, the model
transformation in KADS was found to be a poorly understood process, that is the
technique did not assist the developer in overcoming the bias and information loss
that can occur during the model-transformation phases.
Our approach to the model development is quite different from K-ONCOCIN.
For example, we started conceptual modelling by a knowledge acquisition process,
while K-ONCOCIN started from previous computational models, that, according to
the author, may have provided them with biased preconceptions [19]; in addition, our
model focuses on prognosis and information aspects, while K-ONCOCIN addresses
the complex task of administering cancer therapy; moreover, better results have been
achieved in other application fields (such as, for example, KNOP [16, chap. 11] and
the VT task [20]); finally, the introduction of the CommonKADS CML (Conceptual
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ry of the tumour, in order to select carefully groups of patients with unfavourable
prognosis.
Figure 1 : Qualitative trend of breast cancer in function of the lymph
node status of the primary tumour; positive status is likely to lead to a
poorer prognosis while negative status is likely to lead to a favourable
prognosis; 25/30% of the two categories of patients may have an oppo-
site evolution.
A further problem originates by the fact that present day growth of cancer lit-
erature is of exponential nature (breast cancer is a typical example) [7]. Thousands
of experimental and clinical researchers are actively engaged in cancer research.
Specifically, one of the main aspects which is being increasingly investigated is the
identification of prognostic factors for breast cancer, and specialised journals contin-
uously report a flood of interesting results, at times conflicting; the evaluation of
these results (whether, for example, there is not any bug due to the lack of some as-
pect of the research, or too much hurried conclusions) is also a very complex task
which aims at producing a prognostic guideline.
In conclusion, the prognostic judgement, nowadays often constrained by rigid
protocols, is likely to acquire a better flexibility in the near future, in order to face
better the variability of breast cancer disease; in this case, a knowledge based system

















based system, but in our view, the most interesting application of this model is to be
a base on which building guidelines from literature on cancer, in a future develop-
ment.
2.2 Introduction to breast cancer prognosis and treatment
Breast cancer is an extremely various disease, especially as relates to its evo-
lution. The course of the disease ranges from cases characterised by rapid growth and
tendency to metastasis to cases characterised by low growth generally with favoura-
ble prognosis. Although breast cancer stage determined by diagnosis is one of the
most important prognostic factors, it is known that within neoplasia categories which
may seem homogeneous for clinic-pathological parameters, cases with different ev-
olution can be observed.
Lymph nodes state (positive, N+, vs. negative, N-) is one of the most impor-
tant prognostic factors in breast cancer patients and the one which determines post-
surgical treatment. Patient survival percentage after 5 years in the N- cases is about
67-85%; this value decreases if lymph node metastasis are found (N+) and the de-
crease depends on the number of lymph nodes involved in the pathological process
[1-4]. The research effort towards other prognostic factors is mainly due to the fact
that within the more favourable category (N-) there is a group (about 25-30%) with
unfavourable prognosis (less than 10 years survival) [2, 3] and, in parallel, within the
less favourable category (N+) there is a group (about 25-30%) with favourable prog-
nosis (more than 10 years survival) [4] (fig.1); so it is likely that an inadequate ther-
apy is adopted - specially an “undertreatment” in the N- cases [2,3] - following the
present therapy protocols.
At present, one major research aspect is the identification of one or more prog-
nostic factors accurate enough to define different therapeutic decisions. Prognosis
and selection of therapy are mainly influenced by the age of the patient, stage of the
disease, pathology features of the primary tumour including the presence of tumour
necrosis, oestrogen-receptor (ER) and progesterone-receptor (PR) levels in the tu-
mour tissue, and measures of proliferative capacity, as well as by menopausal status
and general health. Besides, it has been found that these parameters are not sufficient
to define a proper prognosis if they are considered separately.
So, nowadays research mainly directs its efforts towards a characterisation of
the natural history of the tumour, in terms of biological parameters. The biologic pa-
rameters seem to be very promising even if they are currently in phase of study; for
example, ER and PR [5] have already been identified as important prognostic factors.
Good results are expected from other biological parameters, such as, for example,
growth factor receptors like erbB-2 [6]. Each prognostic factor on its own is not suf-
ficient for the prediction of the biological behaviour of the tumour; but a combination
of these parameters is necessary, taking in mind (that is modelling) the natural histo-
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2 Introduction to conceptual modelling in breast cancer
2.1 Introduction to some oncologic problems
Cancer is a group of more than 100 different diseases. Cancer occurs when
cells become abnormal and keep dividing and forming more cells without control or
order. All organs of the body are made up of cells. Normally, cells divide to produce
more cells only when the body needs them. If cells divide when new ones are not
needed, they form a mass of excess tissue, called a tumour. Tumours can be benign
(not cancer) or malignant (cancer). The cells in malignant tumours can invade and
damage nearby tissues and organs. Cancer cells can also break away from a malig-
nant tumour and travel through the bloodstream or the lymphatic system to form new
tumours in other parts of the body. The spread of cancer is called metastasis. Cancer
is treated with surgery, radiation therapy, chemotherapy, hormone therapy, or bio-
logical therapy. The doctor may use one method or a combination of methods. The
choice of treatment depends on the type and location of the cancer, whether the dis-
ease has spread, the patient’s age and general health, and other factors. Many cancer
patients take part in clinical trials (research studies) testing new treatment methods.
Such studies are designed to improve cancer treatment.
Clinical practise guidelines are more and more developing in order to decrease
the delays in implementation of research findings into practise for similar pathology
conditions. This trend is particularly felt in cancer domain, where the decrease in
mortality should be deeply influenced by making state-of-art knowledge and best
medical practices applied to each cancer patient.
Literature review in oncology is a very complex task, as well as the boot for
guidelines development. The central problem originates by the fact that present day
growth of cancer literature is of exponential nature (breast cancer is a typical exam-
ple). Specifically, one among the many aspects which are being increasingly inves-
tigated is the identification of prognostic factors for cancer and for breast cancer in
particular (the more common cancer in women); the evaluation of the flood of, some-
times in conflict, results reported by specialised journals (whether, for example, there
is not any bug due to the lack of some aspect of the research, or too much hurried
conclusions) aims at producing a prognostic guideline.
Although knowledge organisation is rapidly changing in the last few years by
the introduction of hypertext and multimedia techniques, the knowledge resulting
from a research activity is likely to be still presented and recorded by the very authors
in natural language (usually English) for many years. This does not exclude that an
electronic format of the paper, that is of the journal in which the paper has been pub-
lished, will be given for many journals in a brief time.
In this work, we aimed at producing a conceptual model of breast cancer prog-
nosis and treatment. This conceptual model may be used for building a knowledge
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1 Introduction
The research work reported has been carried out in the context of a post-doc-
toral scientific visit in the ACACIA project at the INRIA research centre in Sophia-
Antipolis (France). The ACACIA (Acquisition des Connaissances pour l'Assistance
à la Conception  par Interaction entre Agents) project is a multidisciplinary project
that aims at offering models / methods / tools in order to help the knowledge engineer
to acquire knowledge from multiple expertise sources (experts and documents).
ACACIA project is interested either in capitalizing knowledge on a given domain or
in building an explanatory knowledge based system. The aim is to offer new generic
models in order to help the knowledge engineer to interpret the expertise documents
(for example obtained after elicitation sessions); such models focus on solving prob-
lems of multiple expertises and of explanatory knowledge acquisition. For represen-
tation of expertise models or of acquired knowledge, the formalism adopted is com-
monly in terms of conceptual graphs as well following the methodological frame-
work offered by CommonKADS. Various research is being done on knowledge
acquisition from multiple experts: collective elicitation protocol, model of cognitive
agents for guiding knowledge acquisition, management and comparison of multiple
viewpoints, detection and solving of conflicts among several expertise models, com-
parison of knowledge graphs, generation of consensual rules among experts, archi-
tecture of cognitive agent, extension of CommonKADS for multi-expertise and for
multi-agent systems. The project also works on modelling explanation task and ac-
tivity, on explanation evaluation and on the integration of explanatory knowledge ac-
quisition into a knowledge acquisition method such as KADS. The documentation
aspect is tackled through the exploitation of hypertext techniques for knowledge ac-
quisition and explanations based on electronic documents.
Moreover, although the knowledge acquisition process has mainly regarded
the analysis of documents (papers, books ...), the research work described in this re-
port has also been supported, when needed, by experts from the IST (Institute for the
Study on Tumours) from Genoa.
In the context of this research visit, there have been two main objectives:
• defining a preliminary expertise model for breast cancer prognosis and therapy;
• verifying the potentiality of the CommonKADS methodology to define an exper-
tise model in the medical domain.
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le pronostic et la thérapie
du cancer du sein
Résumé :L’un des principaux aspects de la recherche sur le cancer du sein est
l’identification de paramètres pronostiques suffi amment exacts pour permettre
d’organiser des stratégies thérapeutiques différenciées ; aucun facteur pronostique
n’est suffisant seul pour prédire le comportement biologique d’une tumeur, ais une
combinaison de tels paramètres est indispensable. En outre, la littérature sur le can-
cer, en particulier sur ses aspects biologiques, croît actuellement de façon exponen-
tielle, et la gestion des connaissances dérivant de la recherche sur le cancer aurait
besoin d’une conceptualisation de ces connaissances pour simplifier le processus de
production de guides pour le pronostic et la thérapie du cancer.
Les travaux décrits dans ce rapport se sont focalisés sur la définition d'un modèle
conceptuel des connaissances sur le pronostic et la thérapie du cancer du sein. Nous
avons suivi la méthode CommonKADS et, en particulier, la bibliothèque offerte par
CommonKADS pour la modélisation de l’expertise. Le but de ces travaux était de
fournir une première conceptualisation du pronostic et la thérapie du cancer du sein,
tout en évaluant l’efficacité de la méthode CommonKADS dans ce cadre.
Mots-clé : CommonKADS, acquisition de la connaissance, cancer du sein, domaine
médical.
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Abstract: One of the major aspects in breast cancer research is the identification of
prognostic factors accurate enough to define different therapeutic decisions; each
prognostic factor on its own is not sufficient for the prediction of the biological
behaviour of the tumour, but a combination of these parameters is necessary. Mo e-
over, nowadays growth of cancer literature, specifically on biological aspects, is of
exponential nature, and the management of the knowledge deriving from cancer
research needs a knowledge conceptualisation in order to simplify the process of
guideline production in cancer prognosis and therapy. The work described here
focuses on the definition of a conceptual knowledge model of the prognosis and the
therapy of breast cancer. Our approach to the conceptualisation of the problem fol-
lows the CommonKADS (Knowledge Acquisition and Design Structuring) Library
for Expertise Modelling. The aim of this work is to provide a first conceptualisation
of breast cancer prognosis and therapy, while evaluating the efficacy of the Com-
monKADS methodology in facing the problem.
Key-words: CommonKADS, knowledge acquisition, breast cancer, medical
domain.
(Résumé : tsvp)










appor t  
de  r ech er ch e 
INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET EN AUTOMATIQUE
1995
Using CommonKADS to build an expertise
model for breast cancer prognosis and therapy
Roberto Sacile
N˚ 2737
Novembre 1995
PROGRAMME 3
Intelligenceartificielle,
systèmescognitifs
et interactionhommemachine
